Haemonetics : Q4 2025 Haemonetics Corporation Earnings Release
HAE
Published on 05/08/2025 at 06:14
Olga Guyette, Vice President-Investor Relations & Treasury
Josh Gitelson, Sr. Director-Global Communications
(781) 356-9763 (781) 356-9776
[email protected] [email protected]
David Trenk, Manager-Investor Relations
(203) 733-4987
4th Quarter 2025
Fiscal 2025
Revenue, (decrease) / increase
$331 million, (4)%
$1.361 billion, 4%
Organic1 revenue increase
-%
1%
Earnings per diluted share
$1.17
$3.31
Adjusted earnings per diluted share
$1.24
$4.57
Cash flow from operating activities
$117 million
$182 million
Free cash flow
$95 million
$145 million
1 Excludes the impacts of currency fluctuation, the divestiture of the Whole Blood product line as of its completion in January 2025 and the acquisitions of the Esophageal Protection product line in April 2024 and of the Sensor Guided Technologies product line through the first anniversary of its acquisition in December 2023.
Chris Simon, Haemonetics' CEO, stated: "We delivered solid earnings growth in our fiscal 2025, with record margin expansion and strong cash flow as evidence of the health and vitality of our businesses. Our industry-leading NexSys, TEG and VASCADE technologies continue to propel our growth in attractive markets, and we are on track to deliver all of the goals of our four-year long-range plan in fiscal 2026."
Fourth quarter fiscal 2025 revenue was $330.6 million, down (3.7)% compared with the fourth quarter of fiscal 2024. Business unit revenue and growth rates compared with the prior year period were as follows:
($ millions) 4th Quarter 2025 Reported
Plasma
$126.7
(9.1)%
Blood Center
$56.0
(22.2)%
Hospital
$147.9
12.2%
Total net revenue
$330.6
(3.7)%
Gross margin was 58.4% in the fourth quarter of fiscal 2025, compared with 51.2% in the fourth quarter of fiscal 2024.
The primary drivers of the increase in the gross margin percentage were volume growth in Hospital on higher margin products as well as pricing benefits in all business units, coupled with decreased restructuring costs related to portfolio rationalization initiatives and lower amortization of fair value inventory step-up, partially offset by higher acquisition, integration and divestiture related costs. Operating expenses in the fourth quarter were $121.7 million, a decrease of $24.2 million, or 16.6%, when compared with the prior year period. The decrease in operating expenses was primarily driven by the remeasurement of contingent consideration, lower performance-based compensation and restructuring costs, partially offset by higher acquisition, integration and divestiture-related costs and increased amortization of acquired intangible assets. The Company had operating income of $71.3 million and a 21.6% operating margin in the fourth quarter of fiscal 2025, compared with operating income of $29.9 million and an operating margin of 8.7% in the fourth quarter of fiscal 2024. The income tax rates were 18% and 13% in the fourth quarters of fiscal 2025 and fiscal 2024, respectively. Fourth quarter fiscal 2025 net income and earnings per diluted share were $58.0 million and $1.17, respectively, compared with net income and earnings per diluted share of $20.4 million and $0.40, respectively, in the fourth quarter of fiscal 2024.
Organic revenue for the fourth quarter of fiscal 2025 decreased 0.2% compared with the same period of fiscal 2024 due to the continued transition of CSL's U.S. disposables business in Plasma. Business unit organic revenue growth rates compared with the prior year period were as follows:
Plasma
4th Quarter 2025 Organic
(8.9)%
Blood Center
(0.2)%
Hospital
8.9%
Total net revenue
(0.2)%
Fourth quarter fiscal 2025 adjusted gross margin was 60.2%, up 620 basis points compared with the prior year period. The primary drivers of the increase in the adjusted gross margin percentage were volume growth in Hospital on higher margin products as well as pricing benefits in all business units.
Adjusted operating expenses in the fourth quarter were $116.7 million, a decrease of $4.2 million or 3.4%, when compared with the prior year period. The decrease in adjusted operating expenses was primarily due to lower performance-based compensation and freight costs, partially offset by growth investments. Adjusted operating income for the fourth quarter of fiscal 2025 was $82.3 million, up $17.7 million or 27.5%, and adjusted operating margin was 24.9%, up 610 basis points, compared with the same period of fiscal 2024. The adjusted income tax rates were 22% and 21% in the fourth quarters of fiscal 2025 and fiscal 2024, respectively.
Fourth quarter fiscal 2025 adjusted net income was $61.6 million, up $15.6 million, or 33.8%, and adjusted earnings per diluted share was $1.24, up 37.8% compared with the same period of fiscal 2024.
As part of its previously announced $300 million share repurchase program, the Company repurchased 2,386,131 shares of its common stock for $150 million pursuant to an accelerated share repurchase agreement entered into with Goldman Sachs. The initial delivery of 2,022,245 shares occurred during the fourth quarter, with a final delivery of 363,886 shares completed on April 8, 2025. Accordingly, the Company has completed all repurchases authorized under this prior share repurchase program.
In April 2025, the Company's Board of Directors approved a new share repurchase authorization of up to $500 million of Haemonetics common stock over the next three years. This new share repurchase program will help to offset the dilutive impact of recent and future employee equity grants. In addition to this share repurchase activity, the Company's capital allocation strategy continues to prioritize funding of planned internal investments to support the business as well as inorganic opportunities to accelerate its long-term growth plans.
Under the share repurchase program, the Company is authorized to repurchase, from time to time, outstanding shares of common stock in accordance with applicable laws on the open market, including under trading plans established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in privately negotiated transactions. The actual timing, number and value of shares repurchased will be determined by the Company at its discretion and will depend on a number of factors, including market conditions, applicable legal requirements and compliance with the terms of loan covenants. The share repurchase program may be suspended, modified or discontinued at any time, and the Company has no obligation to repurchase any amount of its common stock under the program.
Cash on hand at March 29, 2025 was $306.8 million, an increase of $128.0 million since
March 30, 2024, primarily driven by debt financing activities and proceeds from divestitures and sales of other assets and property, plant and equipment, partially offset by the Company's acquisition of Advanced Cooling Therapy, Inc. (d/b/a Attune Medical) in early fiscal 2025 and share repurchases.
Cash flow from operating activities was $181.7 million and free cash flow was $144.6 million during fiscal 2025, compared with $181.8 million and $117.3 million in fiscal 2024, respectively. The drivers of nearly flat cash flow from operating activities as compared to the prior fiscal year were increased net income, higher collections of accounts receivable and timing of accounts payable, partially offset by decreased performance-based compensation accruals. Free cash flow was positively impacted by proceeds from the sale of property, plant and equipment and lower additions to Haemonetics equipment compared to prior year, partially offset by higher capital expenditures as compared to the prior fiscal year.
The Company issued its fiscal 2026 GAAP total revenue and organic revenue growth guidance as follows:
Plasma
Blood Center
Hospital
Total Company
Reported
(7 - 10%)
(23 - 26%)
8 - 11%
(3 - 6%)
Currency impact
-
(1) - 0%
-
(1) - 0%
Acquisitions & Divestitures(1)
-
(19%)
-
(4%)
Organic
(7 - 10%)
(4 - 6%)
8 - 11%
(2) - 1%
CSL 2025 US disposables
revenue(2)
21%
-
-
8%
Organic, ex-CSL
11 - 14%
(4 - 6%)
8 - 11%
6 - 9%
1 Reflects adjustment in Blood Center to exclude the impact of the Company's divestiture of its Whole Blood product line in January 2025 and exit of certain liquid solution products.
2 Reflects adjustment to exclude the impact of fiscal 2025 disposable sales to CSL Plasma under its transitional U.S. supply agreement with the Company.
Additionally, the Company issued its adjusted operating margin, adjusted earnings per diluted share, and free cash flow guidance as follows:
Adjusted operating margin 26 - 27%
Adjusted earnings per diluted share $4.70 - $5.00
Free cash flow $160M - $200M
The Company will host a conference call with investors and analysts to discuss fourth quarter and full year fiscal 2025 results on Thursday, May 8, 2025 at 8:00 a.m. ET. The call can be accessed via teleconference at https://register-conf.media-server.com/register/BI8b22e12b203a4693bead05f6d9f68d5d. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.
Alternatively, a live webcast of the call can be accessed on Haemonetics' investor relations website at the following direct link: https://edge.media-server.com/mmc/p/4z9yixt9
The Company has made available on its investor relations website certain supplemental tables that will be referenced during the call and include additional information supporting fiscal 2026 total Company and Hospital reported and organic revenue growth guidance. These supplemental tables can be accessed at the following direct link: https://haemonetics.gcs-web.com/static-files/320de990-2769-4b30-beca-eff1ca68bad1
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit https://www.haemonetics.com.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release may include, without limitation, statements regarding (i) plans and objectives of management for operations of the Company, including plans or objectives related to the Company's strategy for growth; product development, commercialization and anticipated benefits; regulatory approvals; the impact of acquisitions and divestitures; market position and expenditures; and the Company's market and regional alignment and portfolio rationalization initiatives; (ii) estimates or projections of future financial results, financial condition, capital expenditures, capital structure or other financial items, including with respect to the share repurchase program; and (iii) the assumptions underlying or relating to any statement described in points (i) and (ii) above.
Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, availability and demand for the Company's products; the Company's ability to successfully develop and market new products and technologies; the impact of competitive products and pricing; product quality; disruptions caused by cybersecurity events; any failure to realize the anticipated strategic benefits and opportunities from acquisitions and divestitures; pricing pressures resulting from trends toward healthcare cost containment and the effect of industry consolidation; manufacturing, distribution and supply chain disruptions and cost increases; the Company's ability to implement as planned and realize estimated cost savings from the market and regional alignment and portfolio rationalization initiatives; the effects of global economic and political conditions, including changing trade and tariff policies and inflationary pressures; regulatory uncertainties, including in the receipt or timing of regulatory approvals, and the impact of changes in global regulatory conditions; indebtedness incurred by the Company, including the conditional conversion feature of its convertible notes; the Company's ability to protect its intellectual property; litigation; and the impact of share repurchases on the Company's stock price and volatility as well as the effect of short-term price fluctuations on the share repurchase program's effectiveness. These and other factors are identified and described in more detail in the Company's periodic reports and other filings with the U.S. Securities and Exchange Commission (the "SEC"). The Company does not undertake to update these forward-looking statements.
Disclaimer
Haemonetics Corporation published this content on May 08, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 08, 2025 at 10:13 UTC.